Trade Resources Industry Views Alnylam Pharmaceuticals Has Obtained Additional Orphan Drug Designation

Alnylam Pharmaceuticals Has Obtained Additional Orphan Drug Designation

RNAi therapeutics company Alnylam Pharmaceuticals has obtained additional orphan drug designation from US FDA for a RNAi therapeutic, ALN-AT3, to treat hemophilia A.

With the additional approval, orphan drug designation for GalNAc conjugate delivery platform-based ALN-AT3 now includes treatment of both hemophilia A and hemophilia B.

The subcutaneous RNAi therapeutic targeting antithrombin (AT) is being developed for the treatment of hemophilia, including hemophilia A, hemophilia B, and hemophilia A or B with inhibitors, and other rare bleeding disorders (RBD).

Alnylam regulatory affairs and quality assurance senior vice president Dr Saraswathy Nochur said the FDA has granted orphan drug designation for ALN-AT3 now for both the treatment of hemophilia A and hemophilia B.

"As a subcutaneously delivered RNAi therapeutic, we believe it represents an innovative approach for the management of hemophilia and has great potential to make a meaningful impact in the treatment of this often debilitating bleeding disorder," Nochur added.

"ALN-AT3 is a key program in our 'Alnylam 5x15' product development and commercialization strategy, and we look forward to advancing this promising RNAi therapeutic into the clinic in the months to come."

Pre-clinical data demonstrated the ability of ALN-AT3 to normalize thrombin generation and improve hemostasis in hemophilia mice and to fully correct thrombin generation in a non-human primate (NHP) hemophilia inhibitor model.

 

Source: http://regulatoryaffairs.pharmaceutical-business-review.com/news/alnylam-obtains-additional-orphan-drug-designation-for-aln-at3-from-fda-210813
Contribute Copyright Policy
Alnylam Obtains Additional Orphan Drug Designation for ALN-AT3 From FDA